STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANEB
  4. [PRE 14A] Anebulo Pharmaceuticals, Inc. Preliminary Proxy Statement

[PRE 14A] Anebulo Pharmaceuticals, Inc. Preliminary Proxy Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
PRE 14A

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ANEB logo
Anebulo Pharmaceuticals Inc

NASDAQ:ANEB

ANEB Rankings

#4917 Ranked by Market Cap
N/A Ranked by Dividends
#20 Top Gainer

ANEB Latest News

Sep 12, 2025
Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
Jul 23, 2025
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
May 13, 2025
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates
Feb 14, 2025
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
Dec 23, 2024
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise

ANEB Latest SEC Filings

Jul 23, 2025
[8-K] Anebulo Pharmaceuticals, Inc. Reports Material Event

ANEB Stock Data

84.63M
24.43M
40.54%
54.99%
1.1%
Biotechnology
Pharmaceutical Preparations
Link
United States
LAKEWAY